BP's manuscript will be submitted to respected scientific journal and is not a clinical trial, a very different process of review. His science and statistical analysis is perfect. I have read the manuscript 10 times trying to blow holes in it and could not find one. I have communicated with BP. His request for a patent on an assay for rantes is also telling. I just wish I could invest in INTELDX, but it could be an attractive IPO especially my financial house gabs a significant position at the bell.
By the way since there quite an interest in COVID, look into Aperion in Austria, no ADR yet. Since American Regents is a subsidiary of Daiiishki
(on it;s way to their goal to becoming THE largest company in Japan) there could be a joint operating agreement in the future.
It is a monster company with projected stock price to go up significantly and has and ADR, which is publicly traded in the US.